&lt;p&gt;Prognostic Value of Inflammation Biomarkers for Survival of Patients with Neuroblastoma&lt;/p&gt;

Chen, Zheng; Liu, Shuaibin; Feng, Jiexiong; Zhao, Xiaoli

doi:10.2147/cmar.s245622

Cited by 24 publications

(37 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although some studies have suggested that the tumor site was related to the prognosis of NB (16, 17), we did not observe an association between tumor site and survival time in this analysis. Tumor size was identified as an independent predictor of OS and CSS, corroborating evidence reported by recent studies (17,18). However, Zhou et al (19) found that tumor size did not exert a significant prognostic effect on the rate of event-free survival.…”

Section: Discussionsupporting

confidence: 81%

Clinical Characteristics and Survival Outcomes in Neuroblastoma With Bone Metastasis Based on SEER Database Analysis

Mao

Huang

2021

Front. Oncol.

View full text Add to dashboard Cite

PurposeClinical features and survival analysis of neuroblastoma (NB) are well explored. However, clinical research of NB patients with bone metastasis is rarely reported. Thus, the current study was performed to analyze the clinical features, survival outcome, and risk factors in those patients.Materials and MethodsWe reviewed the Surveillance, Epidemiology, and End Results (SEER) database to select cases diagnosed with NB with bone metastasis from 2010 to 2016. Overall survival (OS) and cancer-specific survival (CSS) were analyzed through univariate Cox regression analysis. Subsequently, we performed multivariate analysis to determine independent predictors of survival. The Kaplan–Meier method was applied to intuitively show differences in prognostic value between independent risk factors.ResultsWe finally identified 393 NB patients with bone metastasis who were selected for survival analysis. Nearly half of the patients (47.3%) were aged >3 years. The adrenal gland was the primary tumor site, accounting for approximately two thirds of cases (66.2%). The 5-year OS and CSS rates of all patients were 62.1% and 64.1%, respectively. The univariate analysis indicated that age, lung metastasis, and tumor size were significantly associated with OS and CSS. Based on the multivariable analysis, age at 2 and 3 years, lung metastasis, and tumor size >10 cm remained significant negative predictors of OS and CSS.ConclusionFor NB patients with bone metastasis, three independent prognostic risk factors (age, lung metastasis, and tumor size) are helpful to clinicians for predicting prognosis and guiding treatment. Reasonable treatment modalities for these patients should be further investigated to prolong survival.

show abstract

Section: Discussionsupporting

confidence: 81%

Clinical Characteristics and Survival Outcomes in Neuroblastoma With Bone Metastasis Based on SEER Database Analysis

Mao

Huang

2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…CRP >10 mg/L and albumin <3.5 mg/dl receive one point each, and the score classifies the patients into three total scores of 0, 1, or 2. mGPS does not allocate a score to hypoalbuminemia without a rise in CRP to above 10 mg/L. hs-mGPS provides a similar classification to mGPS with a lower CRP threshold (>3 mg/L) (94,95). These markers also have proven roles in predicting various cancers (94,95).…”

Section: Glasgow Prognostic Score Modified Gps and High-sensitivity Mgpsmentioning

confidence: 99%

Novel Systemic Inflammation Markers to Predict COVID-19 Prognosis

et al. 2021

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has resulted in a global pandemic, challenging both the medical and scientific community for the development of novel vaccines and a greater understanding of the effects of the SARS-CoV-2 virus. COVID-19 has been associated with a pronounced and out-of-control inflammatory response. Studies have sought to understand the effects of inflammatory response markers to prognosticate the disease. Herein, we aimed to review the evidence of 11 groups of systemic inflammatory markers for risk-stratifying patients and prognosticating outcomes related to COVID-19. Numerous studies have demonstrated the effectiveness of neutrophil to lymphocyte ratio (NLR) in prognosticating patient outcomes, including but not limited to severe disease, hospitalization, intensive care unit (ICU) admission, intubation, and death. A few markers outperformed NLR in predicting outcomes, including 1) systemic immune-inflammation index (SII), 2) prognostic nutritional index (PNI), 3) C-reactive protein (CRP) to albumin ratio (CAR) and high-sensitivity CAR (hsCAR), and 4) CRP to prealbumin ratio (CPAR) and high-sensitivity CPAR (hsCPAR). However, there are a limited number of studies comparing NLR with these markers, and such conclusions require larger validation studies. Overall, the evidence suggests that most of the studied markers are able to predict COVID-19 prognosis, however NLR seems to be the most robust marker.

show abstract

“…Previous studies have reported the prognostic values of hs-mGPS, hsCRP/ALB, and PNI in cancers, 14–18 , 27 which were derived from two indicators of hsCRP, LYM, and ALB. To maximize the prognostic performance of these indicators, we combined hsCRP, LYM, and ALB for the first time to construct a new prognostic score, IINS.…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies have reported the prognostic values of hs-mGPS, hsCRP/ALB, and PNI in cancers, [14][15][16][17][18]27 which were derived from two indicators of hsCRP, LYM, and ALB. To maximize the prognostic performance of these [30][31][32] our study revealed the AUCs of 0.591, 0.604 and 0.656 for hs-mGPS, hsCRP/ALB and PNI, which implies the repeatability of our results.…”

Section: Discussionmentioning

confidence: 99%

“…[11][12][13] The high-sensitivity modified Glasgow Prognostic Score (hs-mGPS: the combination of hsCRP and ALB), hsCRP/ALB, and prognostic nutrition index (PNI: the combination of LYM and ALB) have been proposed as predictors for survival of cancer patients. [14][15][16][17][18] A comparative study reported that the prognostic value of Glasgow Prognostic Score (GPS: the combination of CRP and ALB) was better than those of CRP and ALB in patients with hepatocellular carcinoma. 19 A multicenter study also found better prognostic performance of PNI than ALB in patients with pancreatic cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Inflammation-Immunity-Nutrition Score: A Novel Prognostic Score for Patients with Resectable Colorectal Cancer

Yao

et al. 2021

JIR

View full text Add to dashboard Cite

Purpose This study was designed to investigate the prognostic value of the combination of high-sensitivity C-reactive protein, lymphocyte, and albumin in patients with resectable colorectal cancer. Patients and Methods Seven-hundred-and-nineteen patients who underwent colorectal cancer resection in Hubei Cancer Hospital were included. Inflammation-Immunity-Nutrition score (0–6) was constructed based on preoperative high-sensitivity C-reactive protein, lymphocyte, and albumin. Time-dependent receiver operating characteristic curve, decision curve, Kaplan-Meier survival curve, Cox regression, and C-index were conducted to detect the prognostic values of inflammation-immunity-nutrition score. The prognostic values of inflammation-immunity-nutrition score in different subgroups by sex, location of tumor, pathologic stage, and KRAS mutation were also explored. The prognostic performance of inflammation-immunity-nutrition score was further compared with that of other traditional prognostic indicators. Results The median follow-up time was 40 months. High inflammation-immunity-nutrition score (>2 scores) presented worse survival, with the adjusted hazard ratios (95% confidence intervals) of 3.106 (2.202–4.380) for overall survival and 2.105 (1.604–2.764) for disease-free survival. Besides, the associations of high inflammation-immunity-nutrition score with overall survival were even stronger in cases with wild type KRAS , with the adjusted hazard ratios (95% confidence intervals) of 4.018 (2.355–6.854). Considering the AUCs, C-indices, and hazard ratios estimates, inflammation-immunity-nutrition score presented better prognostic performance than high-sensitivity modified Glasgow prognostic score, high-sensitivity C-reactive protein to albumin ratio, prognostic nutrition index, carcinoembryonic antigen, and carbohydrate antigen 19-9 for overall survival. Conclusion Inflammation-immunity-nutrition score might serve as a powerful prognostic score in patients with colorectal cancer for overall survival, particularly in patients with wild type KRAS .

show abstract

<p>Prognostic Value of Inflammation Biomarkers for Survival of Patients with Neuroblastoma</p>

Cited by 24 publications

References 67 publications

Clinical Characteristics and Survival Outcomes in Neuroblastoma With Bone Metastasis Based on SEER Database Analysis

Clinical Characteristics and Survival Outcomes in Neuroblastoma With Bone Metastasis Based on SEER Database Analysis

Novel Systemic Inflammation Markers to Predict COVID-19 Prognosis

Inflammation-Immunity-Nutrition Score: A Novel Prognostic Score for Patients with Resectable Colorectal Cancer

Contact Info

Product

Resources

About